Difference between revisions of "Epirubicin (Ellence)"
m |
|||
| Line 35: | Line 35: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
''The approval of this drug pre-dates the EMA.'' | ''The approval of this drug pre-dates the EMA.'' | ||
| − | + | *1982-06-28: EURD | |
==Also known as== | ==Also known as== | ||
*'''Generic name:''' 4-epi-doxorubicin, epidoxorubicin | *'''Generic name:''' 4-epi-doxorubicin, epidoxorubicin | ||
| Line 70: | Line 70: | ||
[[Category:FDA approved in 1999]] | [[Category:FDA approved in 1999]] | ||
| + | [[Category:EMA approved in 1982]] | ||
Revision as of 13:23, 13 June 2023
General information
Class/mechanism: Anthracycline; binds and intercalates DNA, which triggers DNA cleavage by topoisomerase II; inhibits DNA/RNA synthesis. Inhibits DNA helicase activity, preventing enzymatic separation of double-stranded DNA.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Breast cancer
- Cholangiocarcinoma
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Gallbladder cancer
- Gastric cancer
- Hepatocellular carcinoma
- Classical Hodgkin lymphoma
- Nasopharyngeal carcinoma
- Osteosarcoma
- Small cell lung cancer
- Soft tissue sarcoma
- Testicular cancer
Diseases for which it was used
Patient drug information
- Epirubicin (Ellence) patient drug information (Chemocare)[3]
- Brief patient counseling information can be found on pages 15-16 of the Epirubicin (Ellence) package insert[1]
- Epirubicin (Ellence) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1999-09-15: Initial approval as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. (Based on FASG 05 & NCIC-CTG MA.5)
History of changes in EMA indication
The approval of this drug pre-dates the EMA.
- 1982-06-28: EURD
Also known as
- Generic name: 4-epi-doxorubicin, epidoxorubicin
- Brand names: Alrubicin, Anthracin, Binarin, Bioepicyna, Crisabon, E.P.R Elvetium, Ellence, Epidoxo, Epifil, Epilem, Epirubicine, Epizin, Epricin, Eracin, Famorubicin, Farmorubicin, Farmorubicina, Farmorubicine, Pharmorubicin, Riboepi, Rubifarm
References
- Drugs
- Intravenous medications
- Vesicant
- Anthracyclines
- Topoisomerase inhibitors
- Human DNA synthesis inhibitors
- Breast cancer medications
- Cholangiocarcinoma medications
- Diffuse large B-cell lymphoma medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Gallbladder cancer medications
- Gastric cancer medications
- Hepatocellular carcinoma medications
- Classical Hodgkin lymphoma medications
- Nasopharyngeal carcinoma medications
- Osteosarcoma medications
- Small cell lung cancer medications
- Soft tissue sarcoma medications
- Testicular cancer medications
- Ovarian cancer medications (historic)
- Pancreatic cancer medications (historic)
- FDA approved in 1999
- EMA approved in 1982